Results 101 to 110 of about 3,816 (187)

Potential Benefits of Allogeneic Haploidentical Adipose Tissue-Derived Stromal Vascular Fraction in a Hutchinson–Gilford Progeria Syndrome Patient

open access: yesFrontiers in Bioengineering and Biotechnology, 2020
Hutchinson–Gilford progeria syndrome (HGPS) is a rare, fatal, and genetic disorder in the LMNA gene encoding for prelamin A. Normally, prelamin A is processed to become lamin A protein.
Jaewoo Pak   +7 more
doaj   +1 more source

Potential Role of p53 in Huchinson-Gilford Progeria Syndrome [PDF]

open access: yes, 2017
Undergraduate ...
Eschedor, Danielle   +2 more
core  

A Cell-Intrinsic Interferon-like Response Links Replication Stress to Cellular Aging Caused by Progerin

open access: yesCell Reports, 2018
Summary: Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disease caused by a truncated lamin A protein (progerin) that drives cellular and organismal decline.
Ray Kreienkamp   +9 more
doaj   +1 more source

Organ‐Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming

open access: yesAging Cell, Volume 24, Issue 11, November 2025.
Transient in vivo expression of Yamanaka factors (OSKM) enhances regenerative competence and rejuvenation across multiple tissues. We highlight mechanistic links between injury‐induced dedifferentiation and OSKM reprogramming, while emphasizing safety challenges and the need for precise spatiotemporal control to enable clinical translation.
Beom‐Ki Jo   +4 more
wiley   +1 more source

Structure and stability of the lamin A tail domain and HGPS mutant [PDF]

open access: yes, 2011
Hutchinson–Gilford progeria syndrome (HGPS) is a premature aging syndrome caused by the expression and accumulation of a mutant form of lamin A, Δ50 lamin A.
Buehler, Markus J   +3 more
core   +1 more source

Foetal disruptive brain injuries: Diagnosing the underlying pathogenetic mechanisms with cranial ultrasonography

open access: yesDevelopmental Medicine &Child Neurology, Volume 67, Issue 11, Page 1383-1408, November 2025.
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16431 Abstract Antenatal destructive events affecting the central nervous system of the foetus lead to disruptive brain lesions that are often associated with impaired neurodevelopment.
Ana Alarcón   +33 more
wiley   +1 more source

Impairment of nuclear F-actin formation and its relevance to cellular phenotypes in Hutchinson-Gilford progeria syndrome

open access: yesNucleus, 2020
Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disorder caused by a mutation of lamin A, which contributes to nuclear architecture and the spatial organization of chromatin in the nucleus.
Yuto Takahashi   +8 more
doaj   +1 more source

From Genome to Geroscience: How DNA Damage Shapes Systemic Decline

open access: yesBioEssays, Volume 47, Issue 10, October 2025.
Persistent DNA damage triggers systemic secretory responses including damage‐associated molecular patterns (DAMPs), the senescence‐associated secretory phenotype (SASP), and extracellular vesicles (EVs). This non‐cell‐autonomous signaling disrupts intercellular communication, driving organism‐wide dysfunction and aging, and offering new therapeutic ...
Athanasios Siametis, George A. Garinis
wiley   +1 more source

Unique Preservation of Neural Cells in Hutchinson- Gilford Progeria Syndrome Is Due to the Expression of the Neural-Specific miR-9 MicroRNA

open access: yesCell Reports, 2012
One puzzling observation in patients affected with Hutchinson-Gilford progeria syndrome (HGPS), who overall exhibit systemic and dramatic premature aging, is the absence of any conspicuous cognitive impairment. Recent studies based on induced pluripotent
Xavier Nissan   +9 more
doaj   +1 more source

CURE ID: A Platform to Collect Real‐World Treatment Data for Drug Repurposing in Rare Genetic Disorders

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, Volume 199, Issue 3, Page 189-193, September 2025.
ABSTRACT Rare diseases collectively affect millions of Americans, but less than 5% have approved treatments, and new drug development remains limited. For such diseases, drug repurposing may be an effective strategy to find new treatment options. In the rare genetic disorder community, drugs are frequently prescribed off‐label.
Tahsin Farid   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy